Prof. Olivier DANOS
Prof. Danos is a Research Director at the CNRS. He completed his PhD studies in Virology and Molecular Biology at the Pasteur Institute. With Dr. Richard Mulligan at the Whitehead Institute, he developed retroviral vectors for gene transfer.
At the Pasteur Institute in 1989, he directed the laboratory of “Retrovirus et Transfert Génétique”. He was the Scientific Director of Généthon between 1998 and 2005. He is a member of the INSERM U781 at the “Necker Enfants Malades Hospital” (Paris) and the Director of Gene Therapy Consortium at UCL (London). He sits on several international peer review and expert committees on gene therapy and virology, and has authored over 200 publications in these fields. He is a founding member of the European Society of Gene Therapy (ESGT) and was elected as its president in 1996. Prof. Danos has also served as Senior Scientific Director of Somatix Therapy Corporation.
Dr. Daniel WAGNER
Dr. Wagner is an interventional cardiologist at the Luxembourg general hospital as well as a director of research at the “Centre de Recherche Public” (CRP), the Luxembourg public research institution.
Dr. Wagner has conducted a number of research project and published in numerous international peer reviewed journals. Primarily, Dr. Wagner focuses on the discovery of innovative markers for cardiovascular disorder by working both on new bioinformatics methods intended to discover biomarkers and on the validation of newly discovered biomarkers in clinical practice. The works of Dr. Wagner have resulted in several patents covering the use of certain biomarkers in cardiovascular conditions including heart failure.
Prof. Pierre-Simon ROHRLICH
Prof. Rohrlich graduated as MD in pediatry in 1991 and practiced as an associate professor in Pediatric hemato-immunology at Robert-Debré Hospital in Paris where he specialized in hematopoietic stem cell transplantation.
In 1995, he obtained his diploma in Transfusion Medicine and Immunohematology (DESC). After his PhD of Immunology at Pasteur Institute in 2003, he worked on human CMV infections and on the role of HFE molecules in human physiopathology. His pioneer results on the immune aspects of HFE have been acknowledged worldwide. He has been accredited as research director, and appointed as Professor in Pediatric hematology (PU-PH) at University of Franche-Comté. He is a member of the French National Bio-vigilance committee, lecturer in several academia, a member of University management committee and promoter of several clinical programs in pediatric hematology and immunology. His current interests focus on biomarkers of individual response to immunomodulators.